Company Description
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States.
The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.
It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products.
The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022.
Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
| Country | United States |
| Founded | 1986 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 459 |
| CEO | Paul Josephs |
Contact Details
Address: 3515 Lyman Boulevard Chaska, Minnesota 55318 United States | |
| Phone | (952) 368-4300 |
| Website | lifecore.com |
Stock Details
| Ticker Symbol | LFCR |
| Exchange | NASDAQ |
| Fiscal Year | June - May |
| Reporting Currency | USD |
| CIK Code | 0001005286 |
| ISIN Number | US5147661046 |
| Employer ID | 94-3025618 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Kipling Thacker Ph.D. | Vice President and Chief Scientist |
| Aaron Perlitsh | Director of Internal Audit and Chief Compliance Officer |
| Darren M. Hieber | Senior Vice President of Corporate Development and Partnerships |
| Jackie Q. Klecker | Executive Vice President and GM |
| Matt Augustson | Senior Vice President of Information Technology |
| Parker K. Javid | Vice President |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 29, 2024 | 8-K | Current Report |
| Aug 26, 2024 | 8-K | Current Report |
| Aug 26, 2024 | 10-K | Annual Report |
| Aug 21, 2024 | 8-K | Current Report |
| Aug 12, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Aug 9, 2024 | 10-Q | Quarterly Report |
| Aug 9, 2024 | 10-Q | Quarterly Report |
| Aug 9, 2024 | 10-Q | Quarterly Report |
| Aug 9, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jul 24, 2024 | 8-K | Current Report |